U.S. Markets
Eli Lilly (LLY) has entered into a deal with Ascidian worth up to USD 1.9bln to develop treatments for inherited kidney diseases
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
